Sanfilippo syndrome: Overall review

Pediatrics International - Tập 57 Số 3 - Trang 331-338 - 2015
Fernando Andrade1, Luis Aldámiz‐Echevarría1, Marta Llarena1, María L. Couce2
1Division of Metabolism, BioCruces Health Research Institute, CIBER de Enfermedades Raras (CIBERER), Barakaldo, Spain
2Unit of Diagnosis and Treatment of Congenital Metabolic Diseases Neonatology Service, Department of Pediatrics, CIBER de Enfermedades Raras (CIBERER), IDIS Clinic University Hospital of Santiago de Compostela Coruña Spain

Tóm tắt

Abstract

Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) is a lysosomal storage disorder, caused by a deficiency in one of the four enzymes involved in the catabolism of glycosaminoglycan heparan sulfate. It is characterized by progressive cognitive decline and severe hyperactivity, with relatively mild somatic features. This review focuses on clinical features, diagnosis, treatment, and follow‐up of MPS III, and provides information about supplementary tests and differential diagnosis. Given that few reviews of MPS III have been published, several studies were compiled to establish diagnostic recommendations. Quantitative urinary glycosaminoglycan analysis is strongly recommended, and measurement of disaccharides, heparin cofactor II–thrombin complex and gangliosides is also used. Enzyme activity of the different enzymes in blood serum, leukocytes or fibroblasts, and mutational analysis for SGSH, NAGLU, HGSNAT or GNS genes are required to confirm diagnosis and differentiate four subtypes of MPS III. Although there is no global consensus for treatment, enzyme replacement therapy and gene therapy can provide appropriate results. In this regard, recent publications on treatment and follow‐up are discussed.

Từ khóa


Tài liệu tham khảo

Harris RC, 1961, Mucopolysaccharides disorder: A possible new genotype of Hurler's syndrome, Am. J. Dis. Child., 102, 741

10.1016/S0022-3476(63)80279-6

10.1007/s10545-008-0838-5

10.1002/ajmg.a.20314

10.1007/s004399900075

10.1007/s10545-005-0112-z

10.1002/ajmg.a.33779

10.1038/sj.ejhg.5201044

Neufeld EF, 2001, The Metabolic and Molecular Basis of Inherited Diseases, 3421

10.1073/pnas.75.10.5185

Human Gene Mutation Database. [Cited 17 October 2014] Available from URL:http://www.hgmd.cf.ac.uk/ac/index.php

10.1002/humu.1189

10.1016/0009-8981(82)90168-1

10.1086/508068

10.1086/508294

10.1136/jmg.2004.021501

10.1042/bj2880539

10.1007/s10545-012-9572-0

Lyon G, 2006, Neurology of Hereditary Metabolic Diseases of Children

Wraith JE, 2006, Inborn Metabolic Diseases. Diagnosis and Treatment, 496

Wilkinson FL, 2012, Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PLoS One, 7

10.1111/apa.12169

10.1007/s10545-012-9558-y

10.1097/BPO.0b013e31821f5ee9

10.1016/j.ymgme.2013.03.004

10.1542/peds.2007-0282

10.1007/s10545-013-9661-8

10.1002/ana.22092

10.1080/13803395.2013.804035

10.1007/s10545-010-9199-y

Mellara TS, 2012, Dental findings and management in a mucopolysaccharidosis type IIIB patient, J. Dent. Child. (Chic.), 79, 176

10.1111/j.1399-0004.2010.01525.x

10.1016/j.ymgme.2007.09.011

10.1007/s00415-004-0368-5

10.1002/humu.21234

10.1186/1750-1172-8-189

10.1016/j.cca.2007.10.007

10.1002/mas.20200

10.1016/j.ab.2007.05.016

10.1007/s10545-009-9036-3

10.1016/j.ymgme.2012.09.024

10.1016/j.ymgme.2013.02.001

10.1007/BF01799255

10.1002/pd.1094

10.1016/j.ymgme.2008.05.001

10.1007/s10545-010-9051-4

10.1007/s11064-012-0761-x

10.1007/s00234-004-1215-1

10.1186/1750-1172-6-43

10.1016/j.pcl.2009.11.004

10.1016/j.jpeds.2004.01.052

10.1007/BF01800232

10.1023/A:1005526628598

10.1590/S0004-282X2006000100001

Klein KA, 1995, Poor cognitive outcome of eleven children with Sanfilippo syndrome after bone marrow transplatation and successful engraftment, Bone Marrow Transplant., 15, S176

Bordigoni P, 1989, Correction of Certain Genetic Diseases by Transplantation, 114

10.1089/scd.2005.14.384

10.3727/096368914X676916

10.1007/8904_2014_350

10.1146/annurev.med.57.110104.115650

10.2165/00003495-200767180-00005

U.S. National Institutes of Health. [Cited 21 February 2014] Available from URL:http://clinicaltrials.gov/ct2/show/NCT01155778

10.2174/138920111795542651

10.1002/jgm.1480

10.1038/mt.2011.34

10.1038/gt.2013.14

10.1002/ajmg.a.32861

10.1002/ana.22643

10.1007/8904_2011_87

10.1016/j.ymgme.2013.06.012

10.1016/j.gene.2012.05.006

10.1007/s10545-009-9029-2

10.1007/s10545-013-9668-1

10.1371/journal.pone.0084128

10.1007/s10545-012-9563-1

10.1007/s10545-012-9535-5

10.1016/j.ymgme.2009.10.175

10.1007/s10545-010-9254-8